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Objective: The objective of this study was to examine the mechanism of procoagu-
lant activity and inhibition in whole blood during extracorporeal circulation.
Methods: In this study we examine the development of procoagulant activity and
monocyte activation in heparinized whole blood passing through a closed circuit
consisting of a pump and silicone envelope membrane oxygenator for 6 hours.
Results: Anaphylatoxins, C3a and C5a, determined by means of enzyme-linked
immunosorbant assay, appeared in the blood within 30 minutes of circulation.
Circulated blood developed a marked potential for coagulation demonstrated in a
1-step clotting assay that reached maximal activity by 4 hours of circulation. This
procoagulant activity was neutralized by anti–tissue factor antibody, suggesting a
prominent role for the extrinsic pathway in pump-induced intravascular coagulation.
Isolation of monocytes from circulated blood revealed that tissue factor expression
is upregulated on the cell surface. Furthermore, we observed nuclear factor B
nuclear translocation in monocytes from blood passing through the circuit, suggest-
ing that tissue factor expression was due to monocyte stimulation and transcriptional
activation of the tissue factor gene. Tissue factor expression resulted in an approx-
imately 30-fold increase in thrombin generation. Monocyte nuclear factor B
activation, monocyte tissue factor expression, thrombin generation, and the proco-
agulant activity of blood in extracorporeal circulation were all blocked by the
proteasome inhibitor MG132.
Conclusions: We conclude that intravascular tissue factor expression during extra-
corporeal circulation of blood is due to nuclear factor B–mediated activation of
monocytes (possibly by complement), which can be controlled pharmacologically.
Despite advances in cardiothoracic surgery, there remains consid-erable potential for morbidity and mortality resulting from thewhole-body inflammatory and coagulopathic response caused bycardiopulmonary bypass (CPB). Multiple events contribute to thecoagulopathic response to CPB, including hypothermia, hemodi-lution of clotting factors, and platelet dysfunction. Also, recent
data suggest a prominent role for activation of the extrinsic, or tissue factor
(TF)–dependent, pathway of coagulation in hemostatic abnormalities in patients
subjected to CPB.1-3
The extrinsic pathway of coagulation is initiated when TF contacts and activates
clotting factor VII (VIIa).4 This dual-enzyme complex, TF/VIIa, then activates both
factors IX and X, ultimately resulting in the generation of thrombin and fibrin.
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Normally, TF is constitutively expressed only in the ex-
travascular space. However, under conditions of oxidative
and inflammatory stress, TF expression can be induced on
intravascular cells, such as monocytes and endothelial cells.
The resulting intravascular activation of the extrinsic path-
way of coagulation contributes to a systemic inflammatory
response syndrome and organ failure.5,6
The inducible expression of TF is mediated, in part, by
activation of the transcription factor nuclear factor (NF) B.
NF-B is held inactive in the cytoplasm by IB. During
stress, IB is ubiquitinated and degraded by the protea-
some complex, freeing NF-B to translocate to the nucleus,
where it initiates the transcription of TF, as well as other
proinflammatory and procoagulant genes.7 NF-B also in-
duces transcription of IB to initiate a negative feedback
loop, regulating NF-B–mediated cellular responses. TF
expression also requires the coordinated action of other
transcription factors, including AP-1 and Egr-1.8 Moreover,
NF-B might have other roles in cardiac surgery that in-
clude mediating the cellular responses to oxidative stress
(eg, ischemia-reperfusion injury), microbial invasion, and
mechanical stress, and NF-B mediates activation of ge-
netic programs that control tissue repair. NF-B is now
recognized to have a potential role in programmed cell
death (apoptosis) and the adaptive response to hypoxia.
NF-B might also mediate other cytoprotective functions,
such as preconditioning. Delineating these pathways might
allow the selective modulation of homeostasis to the benefit
of the patient during cardiac surgery and other clinical
settings that require the extracorporeal circulation of blood.
In the present study, using an extracorporeal CPB sys-
tem, we demonstrate NF-B activation in monocytes during
oxygenated pump circulation, which is associated with an
increase in TF expression on monocytes and thrombin gen-
eration in circulated blood. Furthermore, a selective proteo-
some inhibitor, MG132, blocked NF-B activation, TF ex-
pression, and thrombin generation, suggesting that NF-B




Extracorporeal circulation was carried out in a closed system with
surface area/blood volume ratios equivalent to those of a clinical
circuit used for CPB. Each perfusion circuit is assembled from
silicone rubber tubing, polycarbonate connectors, a polyvinyl chlo-
ride venous reservoir bag, and a 0.4-m2 spiral-coil membrane
oxygenator. All components of the circuit were sterilized, and
blood samples were exposed to sterile laboratory equipment. Hu-
man blood (440 mL) was drawn from healthy donors through 16-
or 18-gauge needles and polyvinyl tubing directly into a venous
reservoir bag containing beef lung heparin (5 U/mL) and dextrose
(2.25 mg/mL). The venous reservoir bag for the treatment groups
additionally contained 3 mol/L MG132 (Calbiochem Novabio-
chem Corporation, San Diego, Calif) or proline dithiocarbamate
(ProDTC) at 0.07, 0.21, and 0.42 mg/mL (provided by Norbert
Frank, PhD, German Cancer Research Center). Informed written
consent was obtained from all donors, and the protocols for the
study were approved by the Institutional Review Board of the
University of Washington. Eighteen simulated extracorporeal cir-
cuits were run at 37°C: 6 control, 6 MG132-treated, and 6
ProDTC-treated circuits. All donors were taking no medications 1
week before donating blood.
Blood and gas compartments of the circuits were flushed with
100% carbon dioxide for 15 minutes before priming and then were
evacuated by applying suction to the sample port to debubble. The
system was primed with Plasmalyte electrolyte solution, which is
used clinically. The perfusion circuit was then filled with blood,
avoiding bubble formation. After blood was added, as much prim-
ing volume as possible was removed; this can be compared with
retrograde autologous priming used clinically in CPB. Blood was
circulated for 6 hours at 300 mL/min and 37°C with a calibrated,
barely occlusive roller pump. The oxygenator was ventilated with
a mixture of 95% oxygen and 5% carbon dioxide (0.71 L/min).
Blood was obtained from the venous reservoir before connection
to the circuit and incubated in polypropylene tubes at 37°C for 6
hours before processing. Experimental samples for TF analysis
were taken at 2, 4, and 6 hours of circulation. Experimental
samples for NF-B analysis were taken directly from the venipun-
ture site (baseline) and at 5, 30, 60, and 120 minutes after initiation
of the circuit.
Thrombin Measurement
Citrated plasma was prepared by centrifuging 9 parts whole blood
to 1 part sodium citrate (0.105 mol/L) at 1500g for 10 minutes.
Plasma samples were frozen at 70°C and assayed within 1
month. An F1.2 enzyme-linked immunosorbent assay (Dade Be-
hring, Inc, Deerfield, Ill) based on the sandwich principle was used
for the immunochemical determination of human prothrombin
fragment F 12 in nanomoles per liter.
Monocyte Separation
Ficoll-Paque solution (Pharmacia Corporation, Peapack, NJ) was
used for separation of mononuclear cells, as previously described.1
Two milliliters of blood was withdrawn from the closed circuit
system in ethylenediamine tetraacetic acid–containing tubes and
diluted with 2 mL of Tris-buffered saline solution, pH 7.4. The
diluted blood was carefully overlaid on 3 mL of Ficoll-Paque
solution (Pharmacia) and centrifuged for 35 minutes at 18°C and
400g. The buffy coat, containing monocytes, was isolated and
washed twice with 1 Tris-buffered saline solution at 4°C for 30
seconds. Cells were counted with a Cell Dyn 3500 counter (Abbott
Laboratories, North Chicago, Ill).
Procoagulant Activity Assay
Mononuclear cells (1  107) were diluted 1:1 in type-specific
normal human plasma and incubated for 60 seconds at 37°C.
CaCl2 (8 mmol/L) was added, and clotting time was recorded with
a STA Compact coagulation analyzer (Roche Diagnostics, Basel,
Switzerland) in a 1-stage clotting assay, as previously described.9
Isolated monocytes were incubated with 90 g/mL anti-TF anti-
body (provided by N. Mackman, Scripps Institute) and subjected
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to procoagulant assay, as described above, to ensure that changes
in clotting time are attributable to TF expression. The amount of
TF expressed per 105 monocytes was determined by using a
standard curve described by the following equation:
TF (ng/mL)  e(ln[PCA])  (4.74/0.41).
Nuclear Protein Isolation
The monocyte pellet from 2 mL of whole blood was resuspended
in 400 L of buffer (10 mmol/L N-2-hydroxyethylpiperazine-N-
2-ethanesulfonic acid [pH 7.9], 1.5 mmol/L MgCl2, 10 mmol/L
KCl, 0.1 mol/L phenylmethylsulfonyl fluoride, and 0.5 mmol/L
dithiothreitol [DTT]) and allowed to swell on ice for 15 minutes.
NP-40 (0.6%) was added, and the sample was vortexed for 10
seconds. The sample was centrifuged for 30 seconds, the super-
natant was aspirated, and the pellet was resuspended in 20 L of
buffer (0.5 mol/L dithiothreitol, 0.1 mol/L phenylmethylsulfonyl
fluoride, and 0.01 mg/mL leupeptin). The sample was incubated at
4°C for 15 minutes and centrifuged for 5 minutes at 16,000g. The
supernatant containing nuclear protein was removed and quantified
by means of the standard Bradford assay.
Electromobility Shift Assay
Nuclear protein (10 g) was incubated in a binding reaction with
a double-stranded, 32P end-labeled oligonucleotide containing the
human consensus NF-B binding motif 5-AGTTGAGGG-
GACTTTCCCAGGC-3 (Promega Corporation, Madison, Wis).
Binding reactions occurred at room temperature for 20 minutes.
Proteins were resolved on a 6% nondenaturing polyacrylamide gel
at 100 V for 1 to 2 hours in a 0.5% Tris-borate electrophoresis
buffered solution. The gels were dried and autoradiographed.
Statistical Analyses
Results are expressed as means  SEM. Comparisons of values
between groups at each time point were made by 1-way analysis of
variance.
Results
Complement Activation During Extracorporeal
Circulation
During CPB, blood is in contact with both the polymer
surface and a gas-fluid phase interface. Both these interfaces
activate complement by means of the alternate pathway
generating anaphylatoxins C3a10 and C5a.11 Within 30 min-
utes of the initiation of circulation of blood through the
circuit and membrane oxygenator, levels of C3a increased
sharply and continued to increase gradually for at least 2
hours after initiating circulation (Figure 1). There was a
corresponding increase in levels of C5a (eg, 15-fold at 30
minutes). Soluble C5b-9 terminal complex, also a sensitive
indicator of complement activation, was increased after 30
and 60 minutes of circulation. These values agree with
previous studies using closed-circuit extracorporeal circula-
tion.
Extracorporeal Circulation Induces Procoagulant
Activity in Blood
Blood was sampled at various time points, anticoagulation
was reversed, and the time required for spontaneous clot
formation was observed to determine whether passage of
whole blood through only a CPB circuit resulted in proco-
agulant activity. As shown in Figure 2, A (open circles),
continued exposure of blood to the closed CPB circuit
resulted in a 4-fold reduction in the time for clots to form.
The observed reduction in clotting time began by 2 hours
and shortened progressively until the end of the experiment
(6 hours). This finding indicates development of significant
procoagulant activity in CPB blood induced by the circuit
alone without activation of coagulation by surgical trauma.
Samples at each time point were treated with 90 g/mL TF
Figure 1. Complement is activated in blood during simulated extracorporeal circulation. Whole blood from healthy
donors was circulated through a membrane oxygenator, as described in the “Material and Methods” section. At
time points indicated on the x-axis, blood was withdrawn, and the serum fraction of each sample was assayed
for C3a (A), C5a (B), or soluble C5b9 (C) by means of enzyme-linked immunosorbent assay. Each sample was
measured in duplicate. Values on the y-axis represent the means  SEM for 4 separate experiments.
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monoclonal antibody cocktail (Figure 2, A, closed circles)
to determine whether the procoagulant activity of circuited
blood was due to the presence of TF on blood cells. TF
antibody completely abolished the procoagulant activity,
suggesting that the extrinsic pathway of coagulation is ac-
tivated by passage of blood through the CPB circuit.
Intravascular TF expression requires transcriptional ac-
tivation of the TF gene, which is mediated in part by
NF-B. Therefore, we examined the effect of the treatment
of blood with the NF-B inhibitor MG132 during circula-
tion. MG132 blocks NF-B activation by inhibiting protea-
some degradation of IB.12 The presence of MG132 dur-
ing closed circulation significantly attenuated the reduction
of clotting time in blood after 4 hours of circulation (Figure
2, B). After 6 hours, the reduction in clotting time was still
less in the MG132-treated blood but did not approach sta-
tistical significance compared with the clotting time of
circulated blood not treated with MG132. Of interest, blood
treated with another NF-B inhibitor, ProDTC, did not
inhibit the development of procoagulant activity in blood
passing through a CPB circuit (data not shown).
Monocyte TF Expression
In the absence of red cell hemolysis, the most likely source
of TF in whole blood is the monocyte. We isolated mono-
nuclear phagocytes from blood passing through the closed
circuit, as described in the “Material and Methods” section.
Cell-surface TF was then determined on cultured cells by
means of enzyme-linked immunosorbent assay. As shown
in Figure 3, by 2 hours there was a significant amount of TF
present on mononuclear cells, which peaked at 4 hours. The
expression of TF on monocytes could be substantially in-
hibited when MG132 was added to circulating blood.
NF-B Activation
Monocytes were isolated from samples taken directly from
the venipuncture site and at 5, 30, 60, and 120 minutes after
initiation of blood circulation. Isolated nuclear proteins
were then probed for NF-B by using a DNA double-
stranded probe containing the consensus binding site for the
NF-B p65/p50 heterodimer. In Figure 4, NF-B is acti-
vated in nuclear proteins isolated from mononuclear phago-
cytes of circulated blood. In contrast, NF-B activity was
inhibited when circulated blood was treated with MG132.
Binding activity in these electrophoretic mobility shift as-
says was competed with a cold probe, indicating specificity
for NF-B (data not shown).
Thrombin Generation
Because TF expression results in thrombin generation, we
then assayed the thrombin byproduct F1.2 in our model.
Table 1 shows that significant thrombin generation is de-
tectable in blood at all time points as blood passes through
the closed circuit, particularly at 6 hours, when there is a
Figure 2. Extracorporeal circulation induces procoagulant activity (PCA) in blood. A, After circulation of blood for
various periods of time (x-axis), procoagulant activity, expressed as the length of time required for blood to clot,
was determined in duplicate for each time point. Clotting times were determined in the presence (closed circles)
or absence (open circles) of a saturating amount of anti-TF antibody. B, Drawn blood from healthy donors was
treated with either MG132 (final concentration, 3 mol/L) or an equal volume of vehicle alone. MG132-treated blood
(filled bars) or vehicle control blood (shaded bars) was then circulated through the simulated extracorporeal
circuit; procoagulant activity was determined at the various time points on the x-axis. Values (y-axis) represent
duplicate determinations and the means  SEM of 6 separate experiments.
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29-fold increase in thrombin generation over baseline val-
ues (before circulation). However, treatment of blood with
MG132 abolished thrombin formation during closed circu-
lation of blood through a membrane oxygenator, which is
consistent with MG132-mediated inhibition of NF-B acti-
vation, TF expression on monocytes, and whole-blood pro-
coagulant activity in this closed-circuit model.
Discussion
An intense prothrombotic state during CPB is attributed to
activation of the intrinsic pathway through factor XII after
blood comes in contact with the artificial surfaces of the
extracorporeal circuit. However, recent studies have exam-
ined thrombin generation independent of intrinsic pathway–
mediated coagulation through activation of the TF/factor
VII–dependent pathway during3,13-15 or after16 CPB. Using
a closed-loop extracorporeal circuit to simulate CPB, Kap-
pelmayer and coworkers1 demonstrated that monocyte TF
expression and activity on monocytes in whole blood in-
crease during circulation through the circuit, although the
means of initiation and mechanisms of TF expression on
monocytes were not addressed in that study. Here we dem-
onstrate that TF expression significantly increased between
2 and 6 hours of extracorporeal circulation. We observed
that the onset of TF expression follows the activation of
complement and the generation of C3a, C5a, and sC5b9.
Furthermore, we demonstrate that the transcription factor
NF-B is activated in leukocytes circulating in the extra-
corporeal circuit and that NF-B inhibition with the proteo-
some inhibitor MG132 results in a reduction in both TF
expression and procoagulant activity.
Complement activation, principally through the alternate
pathway, contributes to the systemic inflammatory response
and capillary leak syndrome caused by CPB.17 Complement
anaphylatoxins have been shown to stimulate expression of
numerous proinflammatory mediators that might initiate or
propagate deleterious systemic inflammatory reactions after
CPB. C5a and C3a receptors are present on human mono-
cytes18 and nonmyeloid cells,19 such as vascular endothelial
cells. In vitro, C5a induces expression of interleukin (IL) 1,
IL-6, and IL-8 on human monocytes or in various monocyte
cell lines.20 Earlier studies with rabbit alveolar macrophages
have suggested that C5a might also induce procoagulant
activity on mononuclear phagocytes.21 C5a induces proco-
agulant activity on endothelial cells (in part through upregu-
lation of TF),22 a cell type that responds to several inflam-
matory mediators in a fashion similar to that of monocytes.
Taken together, these observations lead us to suggest that
the upregulation of procoagulant activity on peripheral
blood monocytes during extracorporeal circulation is due to
complement activation and the interaction of C5a (and/or
C3a) with monocytes.
The increased procoagulant activity we measured in ex-
tracorporeal-circulated blood might be due to increased
expression of TF on circulating monocytes.1 Other sources
of TF in vivo, primarily injured vascular tissue and pericar-
dial blood,2 are eliminated in this ex vivo study. Lympho-
cytes and granulocytes are not sources of TF, and platelets
are a target of TF-generated thrombin but do not express TF.
However, activated platelets release platelet factor 4, which
has been reported to induce TF expression on monocytes,
particularly in synergy with lipopolysaccharide stimulation
of monocytes.23 Increases in plasma concentrations of plate-
let granule contents, including platelet factor 4, occur during
Figure 3. MG132 inhibits TF expression on monocytes during extracorporeal circulation. Mononuclear phagocytes
were isolated from circulated blood at various time points indicated on the y-axis. TF expression on surface
membranes was determined by means of enzyme-linked immunosorbent assay, as described in the “Material and
Methods” section. TF expression on monocytes from blood in the extracorporeal circuit was determined for blood
treated with MG132 (3 mol/L) before addition to the closed circuit (filled bars) or after treatment with vehicle
alone (shaded bars). Each datum point was determined in duplicate and represents the mean  SEM of 6 separate
experiments.
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CPB,24 and therefore complement stimulation of TF expres-
sion on monocytes during CPB could be enhanced by CPB-
induced platelet activation. Erythrocytes might induce TF-
dependent extrinsic pathway activation after hemolysis and
might have contributed to the procoagulant response that we
observed. Although we did not specifically measure hemo-
lysis, there was no visual evidence of red cell destruction
after passage through the ex vivo circuit.
The nature of the procoagulant response (reduction in the
time to clot) measured in extracorporeal-circulated blood
was shown specifically to be TF by means of neutralization
with a monoclonal antibody directed against human TF.
Previous work has demonstrated that monocyte membrane
vesiculation and microparticle formation is responsible for
the dissemination of inducible monocyte procoagulant ac-
tivity.25 We did not, however, address this critical aspect of
mononuclear phagocyte biology in our study.
Using gel-shift analysis on isolated mononuclear phago-
cytes, we have demonstrated that the transcription factor
NF-B is activated in circulating nucleated cells of blood in
our closed circuit. TF gene transcription in human mono-
cytic cells exposed to growth factors, bacterial lipopolysac-
charide (endotoxin), or cytokines (tumor necrosis factor or
IL-1) is, in each case, mediated in part by activation of
NF-B. Transcription of the TF gene also requires positive
regulation by AP-1 and Egr-1.8 Whether activation of these
2 transcription factors occurs in blood during extracorporeal
circulation has not been determined.
Under most conditions, NF-B activation requires phos-
phorylation and ubiquitination of IB, the cytoplasmic
inhibitor of NF-B. Proteolysis of ubiquitinated IB oc-
curs at the proteasome, a multicatalytic protease, freeing
NF-B to translocate to the nucleus. Inhibition of protea-
some function with the peptide aldehyde MG132 blocks
IB degradation and NF-B activation in several cell
types stimulated under a variety of conditions.26-28 Although
there is an extensive amount of information on the effects of
MG132 in vitro, little is known about the efficacy of this
potential pharmaceutic intervention in vivo. A related class
of proteasome inhibitors, boronic acids (eg, PS-341), given
orally reduces progression of polyarthritis in a rat model of
bacterial cell wall–induced chronic arthritis.29 Proteasome
inhibition with PS-341 is currently in clinical trials for
treatment of neoplasia.30 However, our study is the first to
investigate the use of a selective proteasome inhibitor to
modify the deleterious effects of a systemic inflammatory
response syndrome during CPB. Because the toxic effects of
peptide aldehydes or boronic acids appear to be minimal in
the in vivo studies in which they were used, the use of such
compounds to improve the systemic response to CPB might
be warranted. ProDTC did not block NF-B activation in
our model of CPB, although dithiocarbamates are consid-
ered to be effective inhibitors of NF-B activation in vitro
in a number of cell types.31 It is unknown why ProDTC
failed to block monocyte NF-B activation under these
conditions.
During contact activation, thrombin is generated and
cleaves fibrinogen to fibrin, promoting thrombus formation.
In addition, thrombin has been shown to stimulate mono-
cyte chemotaxis; phagocytosis; IL-1, IL-6, IL-8, and tumor
necrosis factor production32; and monocyte chemoattractant
protein-1 release.33 The actions of thrombin on leukocytes
occurs through interaction of thrombin with a specific cell-
surface receptor, protease activated receptor-1 (PAR-1).34
Exposure of mononuclear phagocytes to thrombin has been
shown to induce NF-B activation,35 and thrombin activa-
tion of monocytes might include NF-B–dependent TF
expression. Therefore, during CPB, the generation of
thrombin from TF on complement-activated monocytes
could result in further monocyte NF-B activation through
a PAR-1 receptor-mediated mechanism, leading to further
upregulation of monocyte TF expression in a positive feed-
back loop. Of interest, heparin does not appear to interfere
with thrombin/PAR-1 interactions36 and thus would not
block this phase of a procoagulant response during CPB.
In summary, we have demonstrated that complement
activation and generation of the anaphylatoxins C3a and
Figure 4. NF-B activation in monocytes during extracorporeal
circulation is blocked by MG132. Mononuclear phagocytes were
isolated from blood in the closed circuit at the time points
indicated at the top of the lanes. Nuclear proteins were purified
from these cells and probed by means of electrophoretic mobility
shift assay for NF-B translocation to the nucleus. Circulation of
blood was carried out after treatment with MG132 (3 mol/L) or
MG132 vehicle. This figure is representative of 4 similar electro-
phoretic mobility shift assays.
TABLE 1. MG132 inhibits thrombin generation during mem-
brane oxygenation
Time (h) MG132 MG132
2 1.2 0.09 1.3 0.08
4 4.5 0.11 1.4 0.10
6 29.4 95.3 2.1 0.22*
Data are expressed as fold increase of thrombin over baseline.
*P  .05, MG132 versus MG132.
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C5a, a widely known consequence of CPB, possibly ini-
tiates TF expression on monocytes circulated through an
extracorporeal membrane oxygenator. Moreover, we have
found that TF expression on monocytes under these condi-
tions involves activation of the transcription factor NF-B,
which is subject to control through pharmacologic manip-
ulation.
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